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Abstract. The age-related loss of skeletal muscle mass and 
associated progressive decline in contractile strength is a 
serious pathophysiological issue in the elderly. In order to 
investigate global changes in the skeletal muscle proteome 
after the fifth decade of life, this study analysed total extracts 
from human vastus lateralis muscle by fluorescence difference 
in-gel electrophoresis. Tissue specimens were derived from 
middle-aged (47-62 years) vs. aged (76-82 years) individuals 
and potential changes in the protein expression profiles were 
compared between these two age groups by a comprehensive gel 
electrophoresis-based survey. Age-dependent alterations in the 
concentration of 19 protein spots were revealed and mass spec-
trometry identified these components as being involved in the 
excitation-contraction-relaxation cycle, muscle metabolism, ion 
handling and the cellular stress response. This indicates a gener-
ally perturbed protein expression pattern in senescent human 
muscle. Increased levels of mitochondrial enzymes and isoform 
switching of the key contractile protein, actin, support the idea 
of glycolytic-to-oxidative and fast-to-slow transition processes 
during muscle aging. Importantly, the carbonic anhydrase 
(CA)3 isoform displayed an increased abundance during muscle 
aging, which was independently verified by immunoblotting 
of differently aged human skeletal muscle samples. Since the 
CA3 isoform is relatively muscle-specific and exhibits a fibre 
type-specific expression pattern, this enzyme may represent an 
interesting new biomarker of sarcopenia. Increased levels of CA 
are indicative of an increased demand of CO2-removal in senes-
cent muscle, and also suggest age-related fibre type shifting to 
slower-contracting muscles during human aging.
Introduction
Although natural aging of the body may be considered a funda-
mental biological process (1), it is not clear which molecular and 
evolutionary genetic mechanisms trigger the progressive decline 
in physiological functions and decrease the rate of reproduction 
(2). Aging is most likely not due to active gene programming (3), 
but more likely based on evolved limitations in somatic mainte-
nance (4). In humans, one of the most striking features of aging 
is a gradual reduction in skeletal muscle mass and a concomitant 
decline in contractile strength (5). This age-related progressive 
loss of muscle mass and function has been termed sarcopenia 
and is believed to be due to a multifactorial etiology (6-8). As 
reviewed by Berger and Doherty (9), epidemiological studies of 
age-related skeletal muscle wasting indicate that nearly half the 
population over 75 years of age is suffering from some form 
of sarcopenia leading in severe cases to loss of independence. 
Although the findings from a large number of longitudinal and 
cross-sectional studies of skeletal muscle aging (10-19) do not 
concur on the exact rate and extent of contractile tissue loss (20), 
these investigations agree that human aging is associated with a 
general impairment of structural and functional elements of the 
musculoskeletal system (21). Since individual skeletal muscles 
are differentially affected during the natural aging process (22), 
one should be careful about extrapolating age-related changes 
in a particular muscle group to the aging process of the entire 
neuromuscular system.
Muscle wasting occurs in all aged individuals to a varying 
degree (23), but this degenerative process may be accelerated 
by a variety of exacerbating factors, such as lack of physical 
activity, improper nutritional intake, extensive pharmacotherapy 
and/or chronic illness (24). For example, extended periods of 
bed rest in elderly patients are clearly related to inactivity-
induced insulin resistance and further complicate the sarcopenic 
syndrome (25). Advancing age is associated with the loss of 
spinal motor neurons due to apoptosis (26), an impaired capacity 
for axonal re-innervation of deinnervated muscle fibers (27) and 
age-induced low-grade inflammation (28). Histological hall-
marks of sarcopenia are a reduction in fibre numbers, a decline 
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in fibre size and potential loss of entire motor units, whereby 
preferential atrophy of type II fibres has been established as a 
consequence of aging (21,27,29). The diagnosis of sarcopenia 
is based on the combined presence of a low muscle mass and a 
low gait speed (30-32). The clinical cut-off point for sarcopenia 
is considered to be a percentage of muscle mass two standard 
deviations below the mean measured in young adults of the 
same gender and ethnic background, as well as a walking speed 
below 0.8 m/sec in the 4 m walking test (31).
Since a reduction in skeletal muscle mass is pronounced 
in aged lower limb muscle groups, the human vastus lateralis 
muscle has been the center of attention in numerous studies on 
old age (33). Between the ages of 20 and 80 years, the cross-
sectional area of the vastus lateralis muscle may be reduced 
by up to 40% (34,35). Epidemiological studies have indicated 
accelerated muscle wasting after the fifth decade with an 
approximately 2% reduction in muscle mass per year (9). We 
carried out a comparative survey of total extracts from middle-
aged vs. aged vastus lateralis muscle tissue. Fluorescence 
difference in-gel electrophoresis (DIGE) in combination 
with mass spectrometry (MS) was employed to study human 
muscle aging, since this advanced method of modern protein 
biochemistry is capable of swiftly evaluating potential 
changes in large numbers of protein species (36). Over the last 
decade, MS-based proteomics has identified numerous novel 
protein factors involved in myogenesis, muscle differentia-
tion, fibre transitions and various neuromuscular pathologies, 
as summarised in recent reviews (37-39). With respect to the 
natural aging process, proteomics technology has been applied 
to study altered protein expression levels associated with 
cellular changes in skeletal muscle tissues (40), whereby most 
studies have focused on animal models of aging, such as the 
senescent Wistar rat (41-51).
A previous proteomic survey of human muscle aging has 
investigated differences in protein expression between young 
adults (20-25 years) and aged (70-76 years) individuals (52). 
In order to build on these findings and to determine potential 
changes after the fifth decade of life, we used fluorescent 
tagging of the vastus lateralis muscle proteome from middle-
aged (47-62 years) vs. aged (76-82 years) individuals and 
conducted a comprehensive gel electrophoresis-based survey 
of human skeletal muscle aging. Densitometric scanning 
revealed a differential expression pattern for 19 2-dimensional 
(2D) protein spots and the subsequent mass spectrometric 
analysis identified these muscle-associated proteins as being 
involved in contraction, relaxation, ion homeostasis, cellular 
stress response and fibre metabolism. Alterations in key 
muscle proteins from vastus lateralis muscle support the idea 
of generally perturbed protein expression patterns during 
human aging and agree with the notion that sarcopenia is 
associated with the fast-to-slow and glycolytic-to-oxidative 
transition processes (52-54). Of note, the muscle-specific 
carbonic anhydrase (CA)3 isoform (EC 4.2.1.1) (55), which 
has not been previously identified by proteomic surveys of 
human muscle aging (38,52), showed an increase in senescent 
skeletal muscle by both MS-based proteomics and indepen-
dent immunoblot analysis. Elevated levels of CA3 may be 
indicative of an increased demand for efficient CO2-removal 
during fibre aging and/or age-related fibre type shifting to 
slower-contracting muscle populations (54). The establishment 
of a novel biomarker of muscle aging after the fifth decade of 
life may be exploitable for the future development of a more 
reliable assay to diagnose sarcopenia in old age.
Materials and methods
Materials. For the fluorescence 2D-DIGE analysis of aged 
human skeletal muscles, immobilised pH gradient (IPG) 
drystrips pH 3-11, CyDye DIGE Fluor minimal dyes Cy3 
and Cy5, Coomassie Brilliant Blue, ampholytes, acetonitrile, 
cover fluid, and the 2D-Clean-Up kit were purchased from 
Amersham Biosciences/GE Healthcare (Little Chalfont, 
UK). Ultrapure protogel acrylamide stock solutions were 
from National Diagnostics (Atlanta, GA, USA). Sequencing 
grade-modified trypsin for peptide generation was obtained 
from Promega (Madison, WI, USA). LC-MS Formic acid 
and Chromasolv water were purchased from Fluka Chemical 
Corp. (Milwaukee, WI, USA) and spin filters were from Fisher 
Scientific (Loughborough, UK). Chemiluminescence substrate, 
protease inhibitors and nitrocellulose sheets were from Pierce 
and Warriner (Chester, UK), Roche Diagnostics (Manheim, 
Germany) and Millipore (Bedford, MA, USA), respectively. 
For immunoblotting, primary antibodies to the CA3 isoform 
were purchased from Abcam (Cambridge, UK) and secondary 
peroxidase-conjugated antibodies were from Chemicon 
International, Inc. (Temecula, CA, USA). Ultrapure lysine for 
quenching the DIGE labelling reaction, DNase I and all general 
reagents were otained from Sigma Chemical Co. (Dorset, UK).
Human skeletal muscle biopsy samples. Since the neuro-
muscular system of the vastus lateralis muscle is intensively 
studied in human physiology and biochemistry, and frequently 
targeted during biopsy procedures for diagnostic purposes or 
routine biomedical investigations, age-related changes in this 
muscle were studied by MS-based proteomics. Two group-
ings of biopsy material representing healthy middle-aged 
vs. healthy aged vastus lateralis muscle were provided by 
the associated hospitals of the University of Bonn according 
to German ethics regulations (56). Middle-aged specimens 
derived from 47-, 55-, 59- and 62-year-old muscle tissue are 
marked in this study as samples MA1 to MA4. Aged speci-
mens derived from 76-, 77-, 81- and 82-year-old muscle tissue 
are marked as samples OA1 to OA4. Following biopsy, fresh 
tissue specimens were immediately frozen in liquid nitrogen, 
transported on dry ice and then stored at -80˚C prior to usage.
Preparation of urea-soluble fraction of skeletal muscle 
proteome. Freshly thawed skeletal muscle biopsy material 
(100 mg) was ground into a fine powder in the presence of liquid 
nitrogen using a pestle and mortar. Pulverised human muscle 
specimens of different ages were resuspended in 1 ml of ice-
cold buffer containing 7 M urea, 2 M thiourea, 65 mM CHAPS, 
10 mM Trizma base, 1% ampholytes pH 3-11, and 100 mM 
dithiothreitol. In order to eliminate excessive viscosity of the 
protein extract due to large amounts of muscle-derived DNA and 
to minimise protein degradation due to the presence of muscle-
associated proteases, the solution was supplemented with 2 µl 
of DNase I (200 units; Sigma Chemical Co.) per 100 µl buffer 
and a protease inhibitor cocktail (Roche Diagnostics) (57). The 
muscle tissue homogenate was gently mixed by vortexing and 
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then placed on a bench top shaker for 2.5 h at room tempera-
ture to precipitate the total urea-soluble protein complement. 
Following centrifugation of the suspension at 20,000 x g in an 
Eppendorf 5417R centrifuge (Eppendorf, Hamburg, Germany) 
for 20 min, the protein-containing pellet was washed in 5 ml of 
ice-cold 100% acetone and thoroughly broken up by vortexing 
and sonication. Using 80% acetone, washing and centrifuga-
tion was repeated twice and the final protein precipitate was 
collected by centrifugation and resuspended in 1 ml of the 
above described buffer. Individual protein samples were incu-
bated for 1 h at room temperature with careful vortexing every 
10 min for 5 sec. Determination of protein concentration and 
removal of potentially interfering contaminants was performed 
using the Bradford assay system (58) and 2D-Clean-Up kit 
from Amersham Biosciences/GE Healthcare (59), respectively. 
Finally, protein pellets representing middle-aged and aged 
skeletal muscle protein fractions were resuspended in DIGE 
lysis buffer (7 M urea, 2 M thiourea, 30 mM Tris, 4% CHAPS, 
pH 8.5) and adjusted to a protein concentration of 1 mg/ml.
Fluorescence DIGE analysis. The gel electrophoretic separa-
tion of fluorescently tagged muscle proteins was performed 
with a total amount of 100 µg protein per 2D-DIGE gel. To 
keep potential impurities to a minimum, electrophoretic separa-
tion steps were performed under designated fume hoods. For 
each protein preparation derived from differently aged vastus 
lateralis muscle, a 50 µg protein aliquote was fluorescently-
labelled with 200 pmol DIGE fluor dyes for 30 min on ice and 
in the dark. Tissue extracts from eight different muscle samples 
representing 47-82 years of age were each labelled with Cy3 
dye. In addition, pooled internal standards were prepared with 
Cy5 dye, as previously described in detail (60). Quenching of 
the fluorescent labelling reaction was carried out with 10 mM 
lysine for 10 min on ice. For separation in the first dimension, 
isoelectric focusing (IEF) was carried out with 24 cm strips in an 
Amersham IPGphor system using the following running condi-
tions: 30 V for 2 h, 500 V for 2.5 h, 1,000 V for 1 h, 2,000 V for 
1 h, 4000 V for 1 h, 6,000 V for 1 h, 800 V for 3 h, 500 V for 1.5 h 
and finally 8,000 V for 2.5 h. Gel strips were then equilibrated 
for 20 min in reducing buffer containing 100 mM dithiothreitol, 
followed by 10 min of alkylation in buffer containing 250 mM 
iodoacetamide. For separation in the second dimension, slab gel 
electrophoresis was carried out with an Amersham Ettan Dalt-
twelve system, using 12.5% gels. Eight slab gels were run in 
parallel at 0.5 W/gel for 60 min and then 15 W/gel until the blue 
dye front had disappeared from the bottom of the gel. Cy3- and 
Cy5-labelled muscle-associated proteins were visualised with 
the assistance of an Amersham Typhoon Trio variable mode 
imager. Individual 2D-DIGE gels were warped to a single master 
gel prior to analysis. Potential changes in the protein expression 
profile of middle-aged vs. aged skeletal muscle samples were 
analysed using Progenesis SameSpots analysis software from 
Nonlinear Dynamics (Newcastle upon Tyne, UK), using the 
following parameters: n=4; t-test P<0.05; and a power value of 
>0.8. Muscle proteins with a significantly changed density were 
selected for tryptic digestion from Coomassie Brilliant Blue-
stained preparative gels (61).
Mass spectrometric identification of skeletal muscle proteins. 
The mass spectrometric identification of proteins of particular 
interest was carried out in a dedicated and air-conditioned 
proteomics suite with semi-clean analytical status to avoid 
potential contamination of samples. Protein spots were digested 
by standardised in-gel trypsination to generate distinct peptide 
populations (62). MS analysis was performed on a Model 6340 
Ion Trap LC/MS apparatus from Agilent Technologies (Santa 
Clara, CA, USA). Spot excision, washing, destaining and treat-
ment with protease were performed by previously optimised 
methods (57,60,61). Trypsin-generated peptide mixtures were 
dried through vacuum centrifugation and then resuspended 
in MS-grade distilled water and 0.1% (v/v) formic acid, spun 
down through spin filter and added to LC-MS viles for identi-
fication by ion trap LC-MS analysis. A nanoflow Aligent 1200 
series system was employed for peptide separation. Analytical 
samples were loaded into the enrichment at a capillary flow rate 
set to 2 µl/min with a mix of 0.1% (v/v) formic acid and 50% 
(v/v) acetonitrile and formic acid at a ratio of 19:1. The voltage 
was set to 1,700 V. Database searches were carried out with 
Mascot MS/MS Ion search (Matrix Science, London, UK). All 
searches used ‘Homo sapiens’ as a taxonomic category and 
the following parameters: i) two missed cleavages by trypsin, 
ii) mass tolerance of precursor ions ±2.5 Da and product ions 
±0.7 Da, iii) carboxymethylated cysteins fixed modification, 
and iv) oxidation of methionine as variable modification. In 
addition, only hits with at least two matched distinct peptides 
and a Mascot score of at least 44 were considered significant 
proteomic findings.
Verification of age-related changes in the expression of 
carbonic anhydrase by immunoblotting. In order to verify age-
related changes in the abundance of CA, immunoblot analysis 
was carried out to determine the expression levels of the 
CA3 isoform in middle-aged vs. aged vastus lateralis muscle 
preparations. The electrophoretic transfer of muscle proteins to 
Immobilon NC-pure nitrocellulose membranes was carried out 
for 1 h at 100 V and 4˚C with a Mini-Protean transfer system 
from Bio-Rad Laboratories (Hemel-Hempstead, UK). Transfer 
efficiency was routinely evaluated by reversible Ponceau S-Red 
staining of membrane sheets. Nitrocellulose membranes were 
blocked for 1 h in 5% (w/v) fat-free milk powder dissolved in 
phosphate-buffered saline [PBS; 50 mM sodium phosphate, 
0.9% (w/v) NaCl, pH 7.4]. Blocked and washed membranes 
were incubated for 3 h at room temperature with appropriately 
diluted primary antibody to the CA3 isoform, followed by 
a gentle washing in blocking buffer and then incubated with 
an appropriate dilution of peroxidase-conjugated secondary 
antibody for 1 h at room temperature (57). Immuno-decorated 
membranes were washed again in blocking solution and a final 
rinse in PBS. Antibody-labelled protein bands were visualised 
with the SuperSignal-type enhanced chemiluminescence kit 
from Pierce and Warriner. Densitometric scanning of immu-
noblots was performed on a 300 S computing densitometer 
(Molecular Dynamics, Sunnyvale, CA, USA) with ImageJ 
(NIH, USA) and GraphPad Prism (GraphPad Software, Inc., 
San Diego, CA, USA) software.
Results
In order to evaluate age-dependent alterations in the skeletal 
muscle proteome after the fifth decade of life, we applied the 
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fluorescence 2D-DIGE technique and MS for studying vastus 
lateralis specimens from middle-aged vs. aged individuals. In 
our current study, the comparative gel electrophoresis-based 
proteomic study of crude muscle extracts focused on urea-
soluble proteins, which is clearly reflected by the identification 
of mostly soluble and relatively abundant protein species. 
Shown is an overview of the analytical DIGE gels used in 
this proteomic study (Fig. 1), a DIGE master gel outlining 
protein spots with a significant age-related change in abun-
dance (Fig. 2), a listing of changed proteins in senescent vastus 
lateralis muscle as determined by MS analysis (Table I) and 
immunoblotting of changed expression levels in a muscle-
specific protein, the CA3 isoform (Fig. 3). In order to correlate 
MS-identified protein species listed in Table I with distinct 
protein spots of altered concentration in the DIGE master gel 
shown in Fig. 2, the numbering system of proteins in the table 
and corresponding gel is identical.
Proteomic profiling of aging human vastus lateralis muscle. 
In this study, high-resolution fluorescence 2D gel electro-
phoresis, in combination with densitometric analysis using 
a Typhoon Trio variable imager and image analysis with 
progenesis 2D analysis software, resulted in the identification 
of 19 protein spots with a significant change in concentra-
tion levels in middle-aged vs. aged individuals. Shown are 
analytical DIGE gels of protein extracts from 47-, 55-, 59- and 
62-year-old muscle tissue (Fig. 1A-D) and from 76-, 77-, 81- 
and 82-year-old muscle tissue (Fig. 1I-L), labelled with Cy3 
dye. Pooled standards, labelled with Cy5 dye, are depicted in 
Fig. 1E-H and M-P.
MS identification of skeletal muscle proteins with an age-related 
change in concentration. A DIGE master gel with electropho-
retically separated human vastus lateralis muscle proteins is 
shown for a molecular mass range of approximately 10-150 kDa 
and a pI range of pH 3 to pH 11 (Fig. 2). Muscle-associated 
proteins with a potential age-dependent alteration in density 
Figure 1. Two-dimensional (2D) fluorescent difference in-gel electrophoretic analysis of proteins during human skeletal muscle aging. Shown are fluorescent 
2D gels of middle-aged (A-D) vs. aged (I-L) vastus lateralis muscle preparations, as well as pooled standards (E-H and M-P). Specimens MA1 to MA4 were 
derived from 47-, 55-, 59- and 62-year-old muscle tissue, and specimens OA1-OA4 were derived from 76-, 77-, 81- and 82-year-old muscle tissue, respectively. 
MA, middle-aged; OA, old-aged.
Figure 2. Proteomic identification of changed proteins during human skeletal 
muscle aging. Shown is a difference in-gel electrophoresis master gel of total 
protein extracts from vastus lateralis muscle. Skeletal muscle-associated 
proteins with a significantly different expression level are marked by circles 
and are numbered 1-19. Table I displays detailed listing of muscle proteins 
with a changed abundance in aged contractile tissue. The pH values of the 
first dimension gel system and molecular mass standards of the second 
dimension are indicated on the top and on the left of the panel, respectively. 
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ranged in molecular mass from apparent 16.7 kDa (calmodulin) 
to 97.7 kDa (glycogen phosphorylase) and covered a pI range 
from approximately 4.09 (calmodulin) to 8.96 (Acyl-CoA dehy-
drogenase). MS analysis identified 19 proteins species, which 
are listed in Table I outlining protein name, protein accession 
number, molecular mass, pI-value, Mascot score, percentage 
sequence coverage, number of matched peptide sequences, 
Anova score, fold change of individual proteins affected by 
muscle aging, and peptide sequences used to identify proteins. 
The majority of muscle-associated proteins identified by DIGE 
screening in combination with MS analysis were shown to be 
associated with the actomyosin apparatus, the cytoskeleton, 
metabolism, signalling and the cellular stress response. A 
reduced density was determined for 11 proteins and 8 proteins 
showed an increase in their abundance.
The vastus lateralis muscle protein with the highest fold 
decrease was shown in the muscle isoform of α-actin (spots 1, 
2). Phosphoglucomutase (spot 19) was identified as the signifi-
cantly increased enzyme in aged muscle tissue. In addition to 
muscle α-actin, muscle β-actin (spot 9), Annexin (spot 3), DJ-1 
protein (spot 4), troponin subunits (spots 5, 6, 10), glycogen 
phosphorylase (spot 7), heat shock protein (Hsp) β-7 (spot 8), 
and myosin light chain (spot 11) were decreased in senescent 
human muscle. Besides phosphoglucomutase, increased muscle 
proteins were identified as Acyl-CoA dehydrogenase (spot 12), 
Hsp70 (spot 13), CA3 isoform (spot 14), muscle creatine kinase 
(spot 15), succinate dehydrogenase (spot 16), cardiac α-actin 
(spot 17) and calmodulin (spot 18).
In addition to the proteins listed in Table I, the DIGE 
method in combination with MS analysis identified two other 
proteins with a changed abundance in aged muscle; slow 
myosin light chain MLC3 (gi|33563264|; 22523 kDa, pI 5.03) 
and the voltage-dependent anion-selective channel VDAC2 
(gi|6755965|; 32351 kDa, pI 7.44). The contractile protein, 
MLC3, was identified by six peptides (ALGQNPTQAEVLR, 
MMDFETFLPMLQHISK, NKDTGTYEDFVEGLR, 
EGNGTVMGAELR, HVLATLGER and LTEDEVEK) with a 
35% sequence coverage and a Mascot score of 86, and the mito-
chondrial ion channel, VDAC2, was identified by three peptides 
(LTFDTTFSPNTGK, VNNSSLIGVGYTQTLRPGVK and 
LTLSALVDGKSFNAGGHK) with a 17% sequence coverage 
and a Mascot score of 64. Although their identification was 
based on a sufficient number of peptide sequences, the DIGE-
based determination of their respective 2D spots displayed only 
minor fragments. Therefore, these proteins were not included 
in the listing of the main findings of this proteomic survey of 
human skeletal muscle aging.
Immunoblot analysis of CA3 in aging human skeletal muscle. 
Although the DIGE technique represents one of the most 
powerful comparative methods in modern biochemistry and 
MS analysis is highly accurate in identifying distinct protein 
species, we were interested in independently verifying the 
differential expression of a muscle-specific protein identified 
in this proteomic study on old age. Since the CA3 isoform is 
a relatively muscle-specific and fibre type-specific enzyme, 
comparative immunoblotting was carried out to confirm a 
key finding of the proteomic data presented in this study. The 
increased immuno-decoration of CA in aged vs. middle-aged 
specimens from vastus lateralis muscle (Fig. 3A-D) is in 
agreement with the proteomic establishment of higher levels of 
this muscle enzyme in senescent contractile tissue (Fig. 2 and 
Table I). A comparison of 47- vs. 76-year-old, 55- vs. 77-year-
old, 59- vs. 81-year-old and 62- vs. 82-year-old skeletal muscle 
specimens revealed a statistically significant increase in CA3 
isoform expression in senescent skeletal muscle (Fig. 3E).
Discussion
The progressive decline in skeletal muscle mass and the weak-
ening of contractile strength is a major pathophysiological 
feature of the aged neuromuscular system. Often the frailty 
syndrome and muscular dysfunction present personal care 
problems for elderly individuals, limiting their independence 
and requiring them to seek outside help, despite other medical 
ailments (63). This warrants large-scale genomic, proteomic 
and metabolomic surveys of aged skeletal muscle in order to 
establish the underlying mechanisms of sarcopenia in old age. 
Over the last few years, a considerable number of molecular 
investigations involved in the genetic basis of sarcopenia have 
identified a large collection of differentially expressed genes 
in aged muscle tissue (64). Based on these genetic findings, 
it is crucial to verify which of the identified age-dependent 
alterations in gene expression patterns translate into changed 
Figure 3. Immunoblot analysis of carbonic anhydrase CA3 in aged human skeletal muscle. Shown are representative immunoblots labelled with antibodies to 
the CA3 isoform. Lanes 1 and 2 represent middle-aged (MA) vs. old-aged (OA) vastus lateralis (VL) muscle specimens, respectively. Immunoblot panels show 
individual middle-aged samples vs. individual aged samples as follows: (A) 47 vs. 76 years, (B) 55 vs. 77 years, (C) 59 vs. 81 years, and (D) 62 vs. 82 years. (E) 
The comparative immunoblot analysis was statistically evaluated using an unpaired Student's t-test (n=4; *P<0.05).
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concentration levels and/or post-translational modifications 
in distinct protein products that markedly modify skeletal 
muscle functions. The MS-based proteomic survey of human 
aging presented in this study focused on the elucidation of 
potential alterations in the muscle protein complement after 
the fifth decade of life. Our fluorescent DIGE study of the 
vastus lateralis muscle compared middle-aged (47-62 years) 
vs. aged (76-82 years) individuals in order to supplement a set 
of previously determined proteomic data on the same skeletal 
muscle from young adults (20-25 years) and aged (70-76 years) 
individuals (52). Based on the proteome-wide changes 
revealed by these extensive gel electrophoresis-based surveys, 
the illustrative scheme in Fig. 4 summarises our knowledge 
of major molecular and cellular events during human skeletal 
muscle aging. Aged human vastus lateralis muscle tissue, 
which exhibits progressive denervation, faulty re-innervation 
and reduction in cross-sectional area (21,34), is characterised 
by excitation-contraction uncoupling, an altered cellular stress 
response, impaired ion homeostasis, fast-to-slow fibre transi-
tions and glycolytic-to-oxidative metabolic shifts (52-54).
The comparative proteomic study of middle-aged vs. aged 
human muscle identified age-related changes in the expression 
of key proteins involved in the excitation-contraction-relaxation 
cycle, ion handling, the cellular stress response and muscle fibre 
bioenergetics. The apparent switch between the muscle isoform 
of actin with its cardiac counter-part (65) in aged vastus late-
ralis muscle supports the idea of a fast-to-slow transformation 
process in the actomyosin apparatus during skeletal muscle 
aging (54). However, the decrease in slow subunits of the regu-
latory element, troponin, and myosin light chain 2 (MLC2) does 
not follow this general trend of isoform switching in a slower-
twitching aged muscle population. On the other hand, increased 
levels of the mitochondrial enzyme, succinate dehydrogenase, 
clearly support the metabolic concept of glycolytic-to-oxidative 
transitions during fibre aging (53). This proteomic finding 
agrees with the findings from numerous published studies on 
skeletal muscle aging in both rodent models of sarcopenia and 
senescent human muscle (46,50,52). Most likely the observed 
contractile and metabolic transitions are not primary triggering 
events that render an aged skeletal muscle more susceptible to 
the loss of tissue mass and contractile strength, but a patho-
physiological consequence of age-related abnormalities (54). It 
is important to stress that histological studies have established 
that certain aged human skeletal muscles exhibit a consider-
able reduction in fibre numbers, a drastic decline in fibre size 
and high levels of atrophying fast-twitching type II contractile 
fibres (21,27,29). Thus, the overall fast-to-slow transformation 
and glycolytic-to-oxidative metabolic shift during human skel-
etal muscle aging, as revealed by proteomics, possibly reflects 
the preferential loss of fast vs. slower contracting fibres in the 
senescent organism, and not an age-dependent adaptation due 
to enhanced muscle plasticity.
In agreement with the concept of age-related fibre type 
shifting, as exemplified by increased levels of slow contrac-
tile proteins and mitochondrial marker enzymes, is the 
observation of a higher concentration of the muscle-specific 
CA3 isoform (55) in aged human vastus lateralis muscle. This 
relatively abundant enzyme has not been previously identified 
by proteomic surveys of human skeletal muscle aging (38,52). 
CAs are widely distributed throughout the body and catalyse 
the reversible hydration of CO2 (66). The various isoforms play a 
crucial role in the acid-base balance, CO2-removal and provision 
of CO2 for metabolic processes, such as gluconeogenesis and the 
urea cycle, as well as the regulatory processes of ion homeo-
stasis (67-69). Mammalian skeletal muscles express several CA 
isoforms in a fiber type-specific manner, whereby the predomi-
nant CA3 isoform is mostly present in the cytosolic fraction of 
type I and IIa fibers (55). Changes in neuromuscular activity 
patterns, metabolic alterations, stretch-induced hypertrophy 
and disuse atrophy have profound effects on the expression of 
muscle CAs (70-72). Of note, soluble isoforms of muscle CA 
are routinely used in clinical applications for assessing fibre 
Figure 4. Diagrammatic overview of molecular and cellular changes during skeletal muscle aging. The flowchart summarises major age-related changes in 
contractile patterns and muscle metabolism as revealed by proteomic analyses of young adult vs. middle-aged vs. aged human vastus lateralis muscle.
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damage (73). It has been suggested that the muscle-specific CA3 
isoform presents a more sensitive biomarker of muscle damage 
compared to creatine kinase in neuromuscular disorders (74). 
Thus, CA is a well-established biomarker routinely used in 
muscle pathology (75), making it also an ideal candidate for 
evaluating potential fibre type shifting during muscle aging. The 
CA3 isoform levels were shown to be increased in senescent 
human skeletal muscle by both proteomics and independent 
immunoblot analysis. Although a higher concentration of CA3 
may be due to an increased demand for efficient CO2-removal 
during fibre aging, the altered density of this abundant fibre type 
marker is more likely indicative of age-related fibre type shifting 
to slower-contracting muscle populations. In contrast to elevated 
levels of CA3 in aging human skeletal muscle, proteomic 
studies have recently established that the same muscle-specific 
CA isoform is decreased in dystrophic skeletal muscle (76) and 
non-obese, diabetic skeletal muscle (77). This suggests that the 
age-dependent increase in CA3 levels may be relatively specific 
with respect to sarcopenia in old age.
Other altered muscle-associated proteins of interest were 
Annexin A5, DJ-1 protein, glycogen phosphorylase, Hsp β-7 
and Hsp70, creatine kinase, calmodulin and phosphoglu-
comutase. Increased levels of creatine kinase indicate a 
compensatory effect on the creatine phosphate shuttle system in 
aged muscle (78). An altered concentration of Annexin V and 
calmodulin may be due to altered ion handling during aging (79). 
Since calmodulin is a critical factor for Ca2+-sequestration and 
Ca2+-cycling during excitation-contraction coupling (80) and 
also plays a critical role in skeletal muscle plasticity (81), a 
changed density of this abundant Ca2+-binding protein presents 
an excellent new marker of age-related alterations in ion homeo-
stasis. Since many metabolic enzymes involved in glycolysis, 
gluconeogenesis and glycogen metabolism are multi-func-
tional (82), the alterations in phosphoglucomutase and glycogen 
phosphorylase during muscle aging are difficult to interpret. 
Both enzymes are of crucial importance for the bioenergetic 
utilization of muscle glucose. Phosphoglucomutase catalyses 
the inter-conversion of glucose-1-phosphate and glucose 
6-phosphate, and glycogen phosphorylase facilitates the phos-
phorolytic cleavage of a glucosyl-residue from the glycogen 
polymer (83). The decreased levels of glycogen phosphorylase 
and increased density of phosphoglucomutase indicate altered 
flux rates of glucose and glycogen metabolism in senescent 
fibres. It has previously been shown that proteins involved in 
the cellular stress response are changed in various neuromus-
cular disorders (84), including sarcopenia in old age (40). The 
expression levels of various molecular chaperones have been 
shown to be altered after the fifth decade of life. However, 
distinct differences appear to exist between rodent models of 
aging and senescent human muscle (43). Of note, the mostly 
uncharacterised DJ-1 protein, which has been identified in this 
study by MS analysis, has previously been shown to play a role 
in neuro-degeneration (85). This makes this muscle-associated 
protein a potential new marker of sarcopenia.
In conclusion, aging of the human vastus lateralis muscle 
is associated with a plethora of proteome-wide changes, 
especially affecting fibre contraction, ion homeostasis, muscle 
metabolism and the cellular stress response. These proteomic 
findings are in agreement with findings from previous histo-
logical, physiological and biochemical investigations that have 
established cycles of denervation and impaired re-innervation 
causing the loss of entire motor units and muscular atrophy, 
excitation-contraction uncoupling at the triad junction, altered 
functioning of the actomyosin apparatus resulting in weaker 
contractility, impaired regulation of bioenergetic processes, 
disturbed ion handling and an altered cellular stress response 
by molecular chaperones. Importantly, the proteomic data 
presented in this study, are in agreement with altered levels of 
key metabolic enzymes and contractile elements that suggest 
a fast-to-slow transition of the contractile apparatus and a 
glycolytic-to-oxidative shift in metabolism during human 
muscle aging (54). The establishment of a novel biomarker 
signature of muscle aging after the fifth decade of life might 
be exploitable for the future design of a more reliable assay to 
diagnose sarcopenia of old age.
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